The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis
Open accessAbstract
Identification of new drug targets is vital for the advancement of drug discovery against Mycobacterium tuberculosis, especially given the increase of resistance worldwide to first- and second-line drugs. Because traditional target-based screening has largely proven unsuccessful for antibiotic discovery, we have developed a scalable platform for target identification in M. tuberculosis that is based on whole-cell screening, coupled with whole-genome sequencing of resistant mutants and recombineering to confirm. The method yields targets paired with whole-cell active compounds, which can serve as novel scaffolds for drug development, molecular tools for validation, and/or as ligands for co-crystallization. It may also reveal other information about mechanisms of action, such as activation or efflux. Using this method, we identified resistance-linked genes for eight compounds with anti-tubercular activity. Four of the genes have previously been shown to be essential: AspS, aspartyl-tRNA synthetase, Pks13, a polyketide synthase involved in mycolic acid biosynthesis, MmpL3, a membrane transporter, and EccB3, a component of the ESX-3 type VII secretion system. AspS and Pks13 represent novel targets in protein translation and cell-wall biosynthesis. Both MmpL3 and EccB3 are involved in membrane transport. Pks13, AspS, and EccB3 represent novel candidates not targeted by existing TB drugs, and the availability of whole-cell active inhibitors greatly increases their potential for drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 2×
“Bedaquiline) at Johnson & Johnson [4,5].”
Collins, L., & Franzblau, S. G. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1004 · Cited by 1,599
Griffin, J. E., Gawronski, J. D., DeJesus, M. A., Ioerger, T. R., Akerley, B. J., & Sassetti, C. M. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002251 · Cited by 1,048
Self-citationDiarylquinolines target subunit c of mycobacterial ATP synthase
Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio884 · Cited by 547
The Enduring Hypoxic Response of Mycobacterium tuberculosis
Rustad, T. R., Harrell, M. I., Liao, R., & Sherman, D. R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001502 · Cited by 491
Self-citationTuberculosis — metabolism and respiration in the absence of growth
Boshoff, H. I. M., & Barry, C. E. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1065 · Cited by 448
Self-citationSystematic Genetic Nomenclature for Type VII Secretion Systems
Bitter, W., Houben, E. N. G., Bottai, D., Brodin, P., Brown, E. J., Cox, J. S., Derbyshire, K., Fortune, S. M., Gao, L.-Y., Liu, J., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000507 · Cited by 307
Self-citationAltered NADH/NAD + Ratio Mediates Coresistance to Isoniazid and Ethionamide in Mycobacteria
Vilchèze, C., Weisbrod, T. R., Chen, B., Kremer, L., Hazbón, M. H., Wang, F., Alland, D., Sacchettini, J. C., & Jacobs, W. R. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.708-720.2005 · Cited by 284
Self-citation
Cited by
Mycolic Acids: Structures, Biosynthesis, and Beyond
Marrakchi, H., Lanéelle, M.-A., & Daffé, M. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.11.011 · Cited by 623
Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
Andries, K., Villellas, C., Coeck, N., Thys, K., Gevers, T., Vranckx, L., Lounis, N., de Jong, B. C., & Koul, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102135 · Cited by 439
Current and Emerging Legionella Diagnostics for Laboratory and Outbreak Investigations
Mercante, J. W., & Winchell, J. M. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-14 · Cited by 339
Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets
Alsayed, S. S. R., & Gunosewoyo, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065202 · Cited by 332
New agents for the treatment of drug-resistant Mycobacterium tuberculosis
Hoagland, D. T., Liu, J., Lee, R. B., & Lee, R. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.026 · Cited by 328
Metadata
- Authors
- Ioerger, T. R., O’Malley, T., Liao, R., Guinn, K. M., Hickey, M. J., Mohaideen, N., Murphy, K. C., Boshoff, H. I. M., Mizrahi, V., Rubin, E. J., Sassetti, C. M., Barry, C. E., Sherman, D. R., Parish, T., & Sacchettini, J. C.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-09-23
- Volume
- 8
- Issue
- 9
- Pages
- e75245
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2160400589
- Cited by
- 241
- References
- 12
- FWCI
- 15.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis. https://app.cochat.ai/papers/10.1371/journal.pone.0075245
- The paper
- Ioerger, T. R., O’Malley, T., Liao, R., Guinn, K. M., Hickey, M. J., Mohaideen, N., Murphy, K. C., Boshoff, H. I. M., Mizrahi, V., Rubin, E. J., Sassetti, C. M., Barry, C. E., Sherman, D. R., Parish, T., & Sacchettini, J. C. (2013). Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis. PLoS ONE. https://doi.org/10.1371/journal.pone.0075245
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.